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H I G H L I G H T S
 Genotoxic risk of styrene-7,8-oxide (SO) after oral styrene (ST) intake was evaluated.
 Study was based on published results on inhalation genotoxicity of ST or SO in rats.
 A physiological toxicokinetic model predicted blood burdens of SO in rats and humans.
 Genotoxic risk of SO was linked to the SO blood burden.
 A genotoxic risk of SO for humans resulting from ST from food containers is excluded.
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A B S T R A C T
There is potential for oral exposure of humans to styrene (ST) such as from migration of residual levels in
polystyrene food containers. After absorption, ST is metabolised to styrene-7,8-oxide (SO), an alkylating
epoxide. Hence, a comparison of blood burdens of SO resulting from oral exposures to ST was made with
SO burdens possibly warranting genotoxic concern. A validated physiological toxicokinetic model was
used for the assessment. Model calculations predicted for exposures to ST that maximum concentrations
of SO in venous blood of rats and humans should not exceed 0.33 mg/ml and 0.036 mg/ml, respectively,
because of saturation of the SO formation from ST. The daily area under the concentration-time curve of
SO in venous blood (AUCSO) was directly proportional to the dose of ST (mg/kg body weight; BW),
independent of the exposure route (inhalation or oral exposure). In resting humans, the daily AUCSO was
about half that in rats at the same amount of ST/kg BW (calculated up to 100 mg ST/kg BW in humans).
Taking into account the results of cytogenetic studies in ST-exposed rats, it was deduced that no
genotoxic effects of SO are to be expected in ST-exposed humans, at least up to a daily amount of 100 mg
ST/kg BW, which is equivalent to 100 times the amount originating from the Overall Migration Limit in
the EU for ST migrating from food contact plastics. Therefore, no potential genotoxic concern is predicted
for ST uptake from food packaging, based on the reported combined measured and modelled data.
ã 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1.1. Background
Under the European Regulation 793/93 for risk assessment of
existing chemicals the UK submitted a comprehensive evaluation
of the whole toxicological database for styrene (ST). It was
concluded, “there are no concerns for . . . mutagenicity or
carcinogenicity” (UK RAR, 2008). This was the basis for the non-
classiﬁcation of ST for both of these endpoints within the EUrticle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
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“possibly carcinogenic to humans” (Group 2B). The Scientiﬁc
Committee on Health and Environmental Risks (SCHER, 2008)
evaluated the UK RAR (2008). Although SCHER agreed to the major
parts of the UK RAR (2008) regarding genotoxicity and lung
carcinogenicity, they questioned whether the lung is the only
potential target for carcinogenicity.s
The total database for ST shows that most of the studies for
carcinogenicity, mutagenicity and the mode of action refer to the
inhalation route of exposure. This represents the highest potential
exposure to humans, namely for workers exposed in glass-ﬁbre
reinforced industries. On the other hand the vast majority of the
population may be orally exposed to ST, albeit to a much lesser
extent. By this route ST will be nearly completely metabolised to
styrene-7,8-oxide (SO) by ﬁrst-pass liver metabolism and will
enter blood circulation. Therefore, regarding other potential target
organs for carcinogenicity SCHER (2008) agreed “with the
conclusion of IARC (2002), that, based on the observations in
human workers regarding blood styrene-7,8-oxide, DNA adducts
and chromosomal damage, it cannot be excluded that this and
other mechanisms are important for other organs”. Such consid-
erations may have led to the request of the working group on
genotoxicity of EFSA at its 3rd and 4th meetings (March 22–23 and
24–25, 2012; EFSA, 2012a) “that additional in vivo investigations
by oral route should be performed in order to clarify styrene
genotoxicity by oral route”. The basis for this request was explained
in a note of the EFSA working group specifying that although a
number of in vitro and in vivo genotoxicity studies exist, the
database was not considered to be “adequate to clear genotoxicity
of styrene in vivo after oral exposure since most of the in vivo
genotoxicity studies were conducted by different route of
administration” (EFSA, 2012b). In support of its request the group
refers to an in vivo comet assay in the mouse by the intraperitoneal
route with positive ﬁndings in several organs like bone marrow,
blood, liver and kidney (Vaghef and Hellman, 1998). The EFSA
working group noted the signiﬁcant differences in metabolism of
ST between species and tissues and concluded, based on the
toxicokinetic data described in the UK RAR (2008), that rats
represent a better model for humans than mice. It was therefore
proposed to carry out the in vivo comet assay in rats after oral
administration of ST. This note of EFSA (2012b) was the basis for a
request of the European Commission (EC, 2012) to conduct such a
study.
Although IARC (2002) and SCHER (2008) addressed the
possibility of a carcinogenic response in other organs than the lung
of mice, it should be taken into consideration that only the lung of
mice has been identiﬁed as the target organ for carcinogenicity or
precursor effects by inhalation of STas well as by oral exposure to ST.
Thus, similar to lung tumour induction in mice by inhalation (Cruzan
et al., 2001), former non-guideline studies showed some indications
for lung tumours also by the oral route (Ponomarkov and Tomatis,
1978; NCI, 1979). In addition, short-term exposure resulted in
increased cell replication in the terminal bronchioles of mice by the
oral (Green, 1999a) and the inhalation route (Green, 1999b). Cruzan
et al. (2009) presented a mode of action explaining why ST leads to
lung tumours in mice but not in rats similar to some other chemicals
with a comparable carcinogenic proﬁle. Lung tumour formation was
speciﬁcally related to metabolism of ST by the cytochrome P450-
dependent monooxygenase CYP2F2, present in the lung of mice but
not of rats or humans.
To address the request of EFSA (2012b) and the conclusion of
SCHER (2008) the present assessment investigates
- Whether and to what extent the blood burden of SO after oral ST
exposure may be increased compared to inhalation exposure to
ST.- Whether and under what exposure conditions ST may lead to
the formation of SO in concentrations sufﬁciently high to give
reasons for concerns for systemic genotoxic effects and whether
such blood burdens of SO may be attained after oral exposure to
ST.
To this aim, genotoxicity in blood cells was selected as a
sensitive surrogate for systemic genotoxicity.
1.2. Selection of the database
The EFSA working group, when requiring an oral in vivo comet
assay in rats, noted that “the rat would likely represent a more
realistic scenario in terms of metabolic body burden than the
mouse” with respect to the human ST exposure situation.
Therefore the UK RAR (2008) and the IUCLID (last update
September 2014) were searched for mutagenicity/genotoxicity
data in rats. The literature compiled in the IUCLID was based on the
UK RAR (2008) completed by an overlapping literature search from
1998 up to September 2014. The following databases were
searched for toxicology information: CHEMLIST, REGISTRY,
EMBASE and TOXCENTER. The search proﬁle included: acute,
subacute, subchronic, chronic toxicity, irritation to skin and eyes,
sensitization, carcinogenicity, teratogenicity, reproductive toxicity,
neurotoxicity immunotoxicity, endocrine effects, genotoxicity,
mutagenicity, metabolism, alternative methods. One of the authors
(HPG) was responsible for identifying the studies relevant for the
IUCLID (2014) and for the present paper.
For assessment of SO blood burden and its potential genotox-
icity after oral exposure of rats, two rat studies with repeated
inhalation exposures to ST, which measured several different
genotoxicity endpoints, were selected (Sinha et al., 1983 and
Kligerman et al., 1993), based on the UK RAR (2008). In addition, a
more recent investigation reported by Gaté et al. (2012), with
inhalation exposure to ST and SO and measured blood levels of ST
and SO, was included in this analysis. The database is brieﬂy
described below:
1.2.1. Sinha et al. (1983)
Seven to eight-week old male and female Sprague-Dawley rats
were repeatedly exposed by inhalation to ST at concentrations of
600 and 1000 ppm (6 h/d, 5 d/w, 12 months). Thereafter, the
mitotic index as well as the frequency of metaphase aberrations
(chromatid and chromosome type) was determined in femoral
bone marrow cells. At both ST concentrations, there was no
statistically signiﬁcant increased incidence of chromosomal
abnormalities compared to the non-exposed controls. Higher
frequencies of chromatid gaps were not dose-related. This ﬁnding
was considered not to be of toxicological signiﬁcance in the UK RAR
(2008) concluding that the result was overall negative. Thus, ST
was not clastogenic in the rat up to the exposure concentration of
1000 ppm.
1.2.2. Kligerman et al. (1993)
Female Fischer 344 (F344) rats were exposed by inhalation to ST
at concentrations of 125, 250, and 500 ppm for 6 h/d for
14 consecutive days. Thereafter, peripheral blood lymphocytes
were cultured for analyses of sister chromatid exchange, chromo-
somal aberrations, and the micronucleus frequencies in cytocha-
lasin B-induced binucleated cells. The frequencies of micronuclei
were also determined in femoral bone marrow normochromatic
erythrocytes. DNA single-strand breaks were determined in
peripheral blood lymphocytes by means of the alkaline comet
assay. Compared to non-exposed controls, there was neither an
increase in chromosomal aberrations nor one in micronucleus
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However, ST was a weak inducer of sister chromatid exchange.
1.2.3. Gaté et al. (2012)
Male F344 rats were exposed over 6 h to atmospheric
concentrations of SO (25, 50, or 75 ppm) or of ST (75, 300, or
1000 ppm). The SO concentrations in blood resulting from
1000 ppm ST were in between those determined after SO
exposures to 25 and 50 ppm. In order to examine genotoxic
effects of STor SO, too, the exposure schedule for ST and SO was 6 h/
d over 3d or 6 h/d, 5 d/w over 4 w. At the end of the exposures, the
induction of micronuclei in circulating reticulocytes was studied
by means of ﬂow cytometry and DNA strand breaks in leukocytes
caused by DNA adducts by using the “standard” alkaline comet
assay as an indicator test. In addition, the formamidopyrimidine
DNA glycosylase (FPG) modiﬁcation was applied that is speciﬁcally
sensitive for identifying DNA modiﬁcations induced by oxidative
damage or alkylating agents (e.g. Smith et al., 2006). The
micronucleus test and the “standard” comet assay were clearly
negative for both test substances at both time points. On the other
hand, by the FPG modiﬁcation of the comet assay an increased DNA
migration was observed after 3 d of exposure to all three ST
concentrations. Over the whole exposure range of 75–1000 ppm
ST, the effect was quantitatively very similar with no dose-
response relationship. No genotoxic effects were identiﬁed in
blood from rats exposed to ST or SO for 28 d.
1.3. Experimental procedure
An extensively validated physiological toxicokinetic (PT) model
for ST and SO in rodents and humans (Csanády et al., 1994) was
used in order to gain quantitative information about the blood
burden of the genotoxic ST-metabolite SO resulting from the
inhalation studies in rats and from oral as well as inhalation intake
of ST in rats and humans. The following exposure scenarios were
modelled: Inhalation exposures of rats to ST at concentrations of
500 ppm (6 h/d, over 14 consecutive days) according to Kligerman
et al., 1993) and of 75 as well as 1000 ppm (6 h/d, 5 d/w, up to 4 w;Table 1
Biochemical parameters used in the PT model for a male rat and a male human with r
Hepatic enzyme Parameter 












All values are from Csanády et al. (1994) except those marked by * which are from Csaná
Vmaxmo maximum rate of metabolic elimination of ST catalysed by cytochrome P450-de
microsomal epoxide hydrolase; VmaxGST maximum rate of SO conjugation with GSH cata
oxidation related to the ST concentration in venous blood leaving the liver; Kmih intrinsic
compartment; Kmapp apparent Michaelis constant of SO hydroxylation related to the SO
reaction of GSH with GST, related to the GSH concentration in the liver compartment; K
concentration in the liver compartment; CGSH0 initial concentration of GSH in the liver c
order absorption rate constant of ST intake from the gastrointestinal tract.according to Gaté et al., 2012), and to SO at a concentration of
75 ppm (6 h/d, 5 d/w, up to 4 w; according to Gaté et al., 2012). An
extension of the modelled exposure duration of up to one year
according to the study of Sinha et al. (1983) was not done
considering it not to be required. However, the SO burden in
venous blood of a male Sprague-Dawley rat (BW 612 g), exposed
for four weeks (6 h/d, 5 d/w) to 1000 ppm of ST, was simulated by
the PT model. The value of the BW was the estimated average over
the 12-months exposure period in the study of Sinha et al. (1983). It
was calculated by using the information on body weight gain of
male Sprague-Dawley rats fed NIH-31 diet ad libitum (Lewis et al.,
2003). Additionally, inhalation exposures of rats and humans to ST
at concentrations of 9 ppm (rats) and 7 ppm (humans) were
modelled. The exposure conditions (6 h in rats and 8 h in humans)
result in the intake of the same daily amounts of ST as the lowest
modelled amounts of ST taken in orally (see below). This modelling
procedure enables comparison of the SO burden resulting from
two routes of exposure to low amounts of ST. Oral dosing of ST was
modelled as daily intake of a bolus dose and as daily intake of the
same dose divided into three equal parts administered in time
intervals of 3 h to approximate the schedule of food intake of
humans. The cornerstone for modelling oral intake of ST in humans
was the Overall Migration Limit in the EU for substances that can
migrate from food packaging into the foodstuff (OML) of 60 mg/kg
food according to EU (2011) since a Speciﬁc Migration Limit (SML)
has not been established. Considering ST-induced ototoxicity,
reproductive toxicity, and effects on colour discrimination, it has
previously been demonstrated that the OML would be sufﬁciently
protective for human health (Gelbke et al., 2014). Assuming for an
adult a body weight (BW) of 70 kg and a daily food consumption of
1 kg (EC, 2001), the OML corresponds to a daily oral exposure of
approximately 1 mg ST/kg BW. This was taken as the lowest
modelling dose for humans and 100 mg ST/kg BW/d as the highest
modelling dose. The doses for oral exposure of rats (BW, 0.25 kg)
were obtained from those of humans (BW, 70 kg) by allometric
scaling based on BW3/4. This procedure led to 4 mg ST/kg BW/d and
400 mg ST/kg BW/d. As an intermediate dose, 40 mg ST/kg BW/d
was chosen for rats. As intermediate doses for humans, those of theeference body weights of 0.25 kg and 70 kg, respectively.
Rat Human Unit
0.0056 0.002 mmol/h per g liver
0.03* 0.01 mmol/l
0.011 0.0045 mmol/h per g liver
0.021* 0.001 mmol/l
0.1* 0.01 mmol/l






dy et al. (2003). Abbreviations; ST styrene; SO styrene-7,8-oxide; GSH glutathione;
pendent monooxygenase; Vmaxeh maximum rate of SO hydroxylation catalysed by
lysed by cytosolic GSH S-transferase (GST); Kmmo apparent Michaelis constant of ST
 Michaelis constant of SO hydroxylation related to the SO concentration in the liver
 concentration in the liver compartment; KmGSH apparent Michaelis constant of the
mSO apparent Michaelis constant of the reaction of SO with GST, related to the SO
ompartment; kdGSH ﬁrst order elimination rate constant of GSH turnover; kpoST ﬁrst
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the data obtained, the question was addressed whether the
systemic SO burdens resulting from oral exposures to ST may
become sufﬁciently high to give rise to concern of genotoxic
effects.
2. Material and methods
2.1. PT model
Two PT models developed by J.G. Filser’s research group
describe the fate of ST and SO in rodents and humans (Csanády
et al., 1994, 2003). Both deal with the blood burdens of ST and SO,
the newer one additionally with the metabolism and the burdens
of both substances in the airways. Because the goal of the present
work was to predict blood burdens of SO solely, the earlier less
complex PT model was chosen for the present work. Here, the body
is subdivided into 4 compartments consisting of the very richly
perfused tissues and organs, the moderately perfused muscle
group, the slowly perfused adipose tissue, and the liver. Organ- and
tissue-compartments of the PT model are interconnected by the
arterial and venous blood ﬂow. The liver compartment contains a
sub-compartment for SO, the endoplasmic reticulum. ST or SO are
taken in by inhalation or by the oral route.
Metabolism is assigned exclusively to the liver. ST is metaboli-
cally converted to SO by cytochrome P450-dependent monoox-
ygenase. SO is hydrolysed to its glycol by endoplasmic epoxide
hydrolase. It is also conjugated with glutathione by cytosolic
glutathione S-transferase according to an ordered sequential ping-
pong mechanism. Turnover of cytosolic glutathione is described by
zero order production and ﬁrst-order elimination. The sub-
compartment endoplasmic reticulum was required in order to
reﬂect the interaction between cytochrome P450-dependent
monooxygenase and microsomal epoxide hydrolase. As a result
of the functional cooperation of both enzymes in the endoplasmic
reticulum, hydrolysis of SO is more effective with SO formed from
ST than with SO coming from outside across the liver compart-
ment. The non-hydrolysed part of SO in the endoplasmic reticulum
is modelled to be at steady state with the SO concentration in the
liver compartment where SO can be metabolically eliminated via
conjugation with glutathione. Non-metabolized SO enters the
venous blood. The omission of the lung as metabolizing organ is
justiﬁed because ST-metabolism in this organ does not contribute
signiﬁcantly to the systemic SO burden, as was shown for rats and
mice by Hofmann et al. (2006). In human lungs, metabolic ST
oxidation is very small if there is any (Nakajima et al., 1994; Carlson
et al., 2000).
The values of the physiological and biochemical parameters
used in the model were identical to those given in Tables 1 and 2 of
Csanády et al. (1994), with the following exceptions: ThreeTable 2
Measured (Gaté et al., 2012) and PT model-predicted concentrations of styrene (ST)
or styrene-7,8-oxide (SO) in venous blood of 6 w old male F344 rats (estimated
average BW in the seventh week: 130 g), 6 h after starting a single inhalation
exposure to a constant concentration of ST or SO.
Exposure Compound determined Concentration (mg/g blood)
Measured  SD (n = 6) Predicted
SO (25 ppm) SO 0.239  0.098 0.388
SO (50 ppm) SO 0.601  0.193 0.776
SO (75 ppm) SO 0.859  0.430 1.16
ST (1000 ppm) ST 85.5  11.3 94.5
ST (1000 ppm) SO 0.370  0.076 0.313apparent Michaelis constants were changed for rats: the new
values of Kmmo,Kmih, and Kmapp (for abbreviations, see Table 1) were
taken from Csanády et al. (2003) who had revised the original Km-
values of Csanády et al. (1994). The new parameter values, which
were between 77% and 200% of the older ones, enabled a better
agreement of model predictions with measured data. Table 1
summarizes the used biochemical parameters and their values.
In the 2-w study of Kligerman et al. (1993), female rats were
exposed to ST. The animals were 8 w old at the start of the study. In
8–9 w old female rats, the cytochrome-P450 content per g liver was
about 75% of the value in equally old male rats (read from Fig. 2 in
Chengelis, 1988a). A linear extrapolation of the NADPH-dependent
hepatic microsomal activity towards ST in male and female rats
measured at weeks 3 and 18 of life (Table 1 in Kishi et al., 2005) to
week 8.5 gave for females 61% of the value for males. The activities
of hepatic microsomal epoxide hydrolase towards SO and of
hepatic cytosolic glutathione S-transferase towards p-nitrobenzyl
chloride were per g liver of 8–9 w old female rats about 76% and
about 80%, respectively, of the values in equally old male rats (read
from Figs. 2 and 5 in Chengelis, 1988b). Consequently, the values of
Vmaxmo, Vmaxeh, and VmaxGST, all given in Table 1, were multiplied
with 0.70, 0.76, and 0.80, respectively, in order to model the study
of Kligerman et al. (1993).
The PT model does not contain any change in the bioavailability
of ST as a result of repeated exposures. This is in agreement with
ﬁndings of Filser et al. (1993) that repeated exposures of rats to
150 or 500 ppm of ST (6 h/d, 5 d) did not inﬂuence the kinetics of ST
as compared to that in naïve rats. Also Mendrala et al. (1993), when
comparing concentration-time courses of ST and SO in venous
blood of orally ST-dosed (500 mg/kg BW) rats, did not ﬁnd
statistically signiﬁcant (P  0.05) differences in the areas under the
concentration-time curves (AUC) for ST (AUCST) or SO (AUCSO) in
venous blood between animals pre-treated with ST (1000 ppm;
6 h/d, 4 d) or naïve ones.
The PT model was described by a series of mass balance
differential equations (see Csanády et al., 1994). In the cited
publication, there was a typographical error in equation 5. The
correction is shown in equation 13 in Csanády et al. (2003). The
differential equations were solved numerically on a Mac computer
using the program Berkeley Madonna X (version 8.3.22).
BWs of F344 rats in dependence of age (up to 13 w) were
obtained from the Gene Editing Rat Resource Center (2013). For rat
ages that were between the reported ones, BWs were linearly
interpolated. If the BW of a rat differed from the reference value of
0.25 kg, its inﬂuence on physiological parameters and maximum
rates of ST and SO metabolism was taken into account by
allometrically scaling cardiac output, alveolar ventilation, and
the maximum rates Vmaxmo, Vmaxeh, and VmaxGST (see Table 1) using
a body surface scaling factor of BW2/3 (e.g. Filser, 1992). The
inﬂuence of physical activity on alveolar ventilation, cardiac
output, and blood ﬂow through the liver was taken into account by
revising the values of these parameters according to Csanády and
Filser (2001).
AUCs of ST or SO in blood from t = zero to inﬁnity were
calculated up to the last data point of the concentration-time curve
using GraphPad Prism, version 6 for Macintosh (GraphPad
Software, La Jolla California USA) and adding the ratio of the
concentration at the last data point to the rate constant of the ﬁnal
elimination phase. The same program was used to calculate linear
regression curves.
2.1.1. Validation of the PT model
The quality of the model was demonstrated for humans by
comparing predicted concentrations of ST and SO in venous blood
of ST-exposed workers against values measured by Korn et al.
(1994); see Fig. 1. For rats, model-predicted concentrations of SO in



































Fig. 1. Styrene (ST, A) and styrene-7,8-oxide (SO, B) in venous blood of 13 male workers exposed to vaporous ST (10.6–72.6 ppm) for time frames of between 248 and 325 min.
Measured individual data points (taken from Korn et al., 1994) are symbolised by for ST and by * for SO. The curves were predicted by the PT model for a human of 70 kg
BW with an alveolar ventilation of 410 l/h. Exposure to constant concentrations of ST was modelled to last 287 min. The data points at the origin were from unexposed persons.
J.G. Filser, H.-P. Gelbke / Toxicology Letters 247 (2016) 11–28 15venous blood were plotted against corresponding experimental
data obtained following inhalation of ST (Kessler et al., 1992; Filser
et al., 1992; Cruzan et al., 1998; Gaté et al., 2012); see Fig. 2. Also,
model-predicted concentration-time curves of ST and SO in venous
blood resulting from oral administration of ST were compared withvalues measured by Mendrala et al. (1993); see Fig. 3. An additional
comparison is given in Table 2 that shows measured and PT model-
predicted concentrations of SO in venous blood of rats that were
single-exposed (6 h) by inhalation to various concentrations of SO
or ST and SO in venous blood of rats that were exposed (6 h) to

















Fig. 2. Concentrations of styrene-7,8-oxide (SO) in venous blood of male rats exposed for 6 h to atmospheric concentrations of styrene (ST) ranging from 0 to 1000 ppm.
Measured data had been published (Kessler et al., 1992; Filser et al., 1992, Sprague-Dawley rats *; Cruzan et al., 1998, Sprague-Dawley rats ~; Gaté et al., 2012, F344 rats ^).
Bars represent reported SDs. The curve was predicted by the PT model for a rat with a BW of 225 g, the average of the BWs of the rats used by Kessler et al. (1992) and Filser et al.
(1992).
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concentrations in Table 2 were within the standard deviations (SD)
of the measured data with the exception of one value predicted for
the lowest SO exposure concentration of 25 ppm. It was little above
the reported SD range.
Figs. 1 and 2 and Table 2 demonstrate that the model-
predicted concentrations of ST or SO in venous blood of humans
and rats, which result from inhalation exposures to ST (humans)
and to both compounds (rats), were in agreement with the
measured data. Cruzan et al. (1998), when determining SO in the
blood of 95-week-old ST-exposed rats, found somewhat lower SO
concentrations than the other authors (Fig. 2). The difference
might result from the higher activity of hepatic epoxide hydrolase
towards SO in senescent as compared to young male rats
(Birnbaum and Baird, 1979; Chengelis, 1988b). A publication
most relevant to the present investigation was that of Mendrala
et al. (1993 because it enabled a direct comparison of measured
and model-predicted concentration-time courses and of AUCs of
both ST and SO in venous blood of rats resulting from oral
administration of ST. The AUCST of the predicted concentration-
time curve of ST (723 mg h/ml) was about twice as large as that
reported on the basis of measured data (367  81 mg h/ml), the
predicted concentration-time curve of the metabolite SO had an
AUCSO (4.39 mg h/ml) that was within the SD range of the
reported one (3.32  1.20 mg  h/ml).
Given the agreement between measured and predicted data in
rats and humans, the PT model was applied for the following
modelling exercise.
3. Results and discussion
3.1. Inhalation studies of Kligerman et al. (1993) and Gaté et al. (2012)
3.1.1. Kligerman et al. (1993)
The authors exposed female F344 rats by inhalation to
atmospheric concentrations of ST of up to 500 ppm for 6 h/d for
14 consecutive days. In order to acquire information on the SO blood
burden resulting form the exposure to 500 ppm ST, the exposurescenario and the resulting concentration-time curve of SO in venous
blood was calculated by the PT model (Fig. 4). At each exposure day,
the concentration of SO in venous blood increases continuously
during the 6-h exposure to ST until a sharp peak of 0.252mg SO/ml
blood is reached. Immediately thereafter, it declines rapidly until
reaching the baseline 18 h later. Similarly, the concentration of the
metabolic precursor ST in the venous blood rises during the daily 6-h
exposure to a short peak of 41 mg/ml blood (ﬁrst week of exposure).
Then it drops rapidly to baseline at the end of each 24-h period.
During the second week, ST-peaks are a little less high (calculated
concentration-time curve of ST not shown). Under such exposure
conditions, SO does not accumulate in the rat, thus the daily SO peaks
are level.
3.1.2. Gaté et al. (2012)
Gaté et al. (2012) exposed rats to vapourous ST (75, 300, or
1000 ppm; 6 h/d, 3 d or 6 h/d, 5 d/w, 4 w) or to SO (25, 50, or
75 ppm; 6 h/d, 3 d or 6 h/d, 5 d/w, 4 w). Of these scenarios, the 4-w
exposures to the lowest and the highest concentrations of ST and
to the highest concentration of SO were simulated by means of
the PT model. Model-calculated concentration-time curves of ST
and SO in venous blood of rats exposed to 75 ppm and 1000 ppm
of ST are shown in Figs. 5 and 6. Fig. 7 depicts the model-
calculated concentration-time curve of SO in the venous blood of
a rat that is exposed over the same time period to 75 ppm of SO. ST
concentrations in venous blood of the animals exposed to 75 ppm
of ST rise to peak concentrations of 1.57 mg/ml during the ﬁrst
week of exposure (Fig. 5). The maximum peaks of ST reached
during the ﬁrst week of exposure to 1000 ppm of ST are 94.6 mg/
ml (Fig. 6). The disproportionate increase in the blood concen-
trations of ST from 75 to 1000 ppm results from the saturation
kinetics of the ST metabolism. At the high exposure concentra-
tion, the metabolic elimination of ST is relatively slower and takes
longer than at the low exposure concentration. As a consequence,
ST enriches disproportionately in the body, predominantly in the
fatty tissue, an effect demonstrated by Filser et al. (1993). The less
than proportional increase in the maximum SO concentration in
venous blood (CmaxSO) from exposures to 75 and 1000 ppm ST






























Fig. 3. Concentration-time courses of styrene (ST, A) and styrene-7,8-oxide (SO, B) in blood of male F344 rats after oral administration of 500 mg ST/kg BW. Measured data (ST:
SO: *) SDs from Mendrala et al. (1993). Minus SDs that were smaller than the smallest value on the y-axis are not shown. The limit of quantiﬁcation of SO was 0.010 mg/
ml blood. The curves were predicted by the PT model for a rat with a BW of 174 g, the average of the BWs of the rats used by Mendrala et al. (1993).
J.G. Filser, H.-P. Gelbke / Toxicology Letters 247 (2016) 11–28 17(Figs. 5 and 6; Table 3) results also from the saturation kinetics of
ST: The SO formation is relatively slower at the high ST-
concentration than it is at the low one. Therefore, the curve in
Fig. 2 showing the SO concentration in rat blood in dependence of
the ST exposure concentration reaches a plateau at high exposure
concentrations when the maximum rate of the metabolism of ST
to SO is reached.
Considering that the calculated CmaxSO value of the SO exposed
animals (Fig. 7) was 24- and almost 4-fold higher than the CmaxSO
values in the rats that were exposed to 75 and 1000 ppm of ST
(Figs. 5 and 6, and Table 3), it becomes evident that the DNA
damage observed in the presence of FPG in circulating leukocytes
of the 3-d ST-exposed but not of the SO exposed rats (Gaté et al.,
2012) could not result from metabolically produced SO. Themaximum concentrations of ST in venous blood of the animals
exposed to 75 ppm of ST were calculated by the PT model to be
60 times lower than of those exposed to 1000 ppm of ST (compare
Figs. 5A and 6A). However, the rather small DNA damage (in
average 1.9 or 6.9 times higher than the damages found in two
independent FPG-containing controls) was not dose-dependent,
although ST exposure concentrations ranged from 75 up to
1000 ppm. It is hard to explain how the DNA damage could result
from ST. In order to interpret their ﬁndings of increased DNA strand
breaks after 3 d of exposure to ST but neither after 20 d of exposure
to ST nor after 3 or 20 d of exposure to SO, Gaté et al. (2012)
speculated “a possible cellular adaptation to genotoxic insults”.
The authors suggested also oxidative stress induced by ST or by an
ST-metabolite other than SO as the source of the DNA damage















Fig. 4. PT-model-calculated concentration-time curve of styrene-7,8-oxide (SO) in venous blood of a female F344 rat exposed by inhalation to vaporous styrene (ST) at a
concentration of 500 ppm for 6 h/d for 14 consecutive days (according to the experimental design of Kligerman et al., 1993). At the start of the study, the rat was 8 w old. BW
was set to 130 g and 141 g for the ﬁrst and the second week of exposure, respectively.
18 J.G. Filser, H.-P. Gelbke / Toxicology Letters 247 (2016) 11–28found after 3 d in the presence of FPG. However, the fact that the
extent of this damage was not dependent on the ST concentration
does not support these hypotheses. One possible explanation is
that the statistically signiﬁcant difference from the controls is
actually a random result. (A more detailed assessment of the comet
assay performed by Gaté et al. (2012) in circulating white blood
cells in the presence of FPG is given in the Appendix A). Whatever
might be the biological signiﬁcance of the DNA damage described
for ST after 3 d of exposure in the FPG modiﬁcation, this study
clearly shows that SO does not lead to systemic genotoxicity in
peripheral blood.
During the exposure to 75 ppm of ST, the rate of ST oxidation is
by far below its maximum value (Vmaxmo); Concentrations of ST
and its metabolite SO in venous blood decrease rapidly after the
end of each exposure (Fig. 5). At exposures to 1000 ppm of ST
(Fig. 6), the metabolic elimination of ST is almost saturated. As a
consequence of the limited metabolic ST elimination, ST enriches
to relatively higher concentrations in the organism and the
enrichment phase is longer as compared to lower exposure
concentrations at which metabolism is not saturated. Additionally,
the allometrically scaled alveolar ventilation (a measure of the gas
exchange rate between the exposed organism and the surrounding
air) is relatively smaller in heavier compared with lighter animals.
Hence, during the 6-h exposures to 1000 ppm of ST, lower
maximum concentrations of ST are reached in the venous blood
of the older (heavier) than in that of the younger (lighter) rats
(Fig. 6). At low exposure concentrations of ST, this effect is less
evident (Fig. 5). The SO peak curves at exposures to 1000 ppm of ST
(Fig. 6) due not drop to the baseline at the end of each exposure day
in contrast to those at exposures to 500 or 75 ppm of ST (Figs. 4 and
5). However, even at 1000 ppm of ST, there is almost no SO
accumulation of the daily exposures. Also, after exposure to
75 ppm of SO the epoxide does not accumulate in spite of the much
higher SO concentrations reached at the end of each exposure
period (Fig. 7).
A comparison of the model-calculated declines of SO after the
end of the daily exposures in Figs. 4–6 with those in Fig. 7demonstrates much slower decline rates following exposure to ST
than after exposure to SO. Obviously, the elimination rate of ST
limits the elimination rate of SO when it is formed metabolically.
Fig. 7 shows about 4 times higher SO maxima from exposure to
only 75 ppm of SO than those that are reached during exposure to
1000 ppm of ST (see also Table 3).
3.2. SO in blood after oral intake of ST
3.2.1. Rat
Figs. 8 and 9 show PT-model-calculated concentration-time
curves of SO in venous blood of a rat with a BW of 250 g. Several
conditions of ST intake were modelled: either daily (5 d) single
oral bolus doses of 400, 40, or 4 mg of ST/kg BW (Fig. 8) or daily
(5 d) three times in time intervals of 3 h repeated orally
administered doses of each 400/3, 40/3 or 4/3 mg of ST/kg BW
(Fig. 9). Daily bolus doses of ST result in higher values of CmaxSO
than divided doses. The effect is less evident when comparing the
largest single dose with the largest divided one because
metabolism of ST to SO is almost saturated after the second
administration of the divided dose. The SO peaks resulting from
the largest dose of ST (administered as a bolus or as a divided dose)
are broader than those from the smaller doses. This is a
consequence of the saturation of the ST metabolism: it takes a
while until the concentration of ST in the liver is low enough so
that its elimination and, as a consequence, that of SO follows ﬁrst-
order kinetics. There is no accumulation of SO after multiple oral
dosing, even after the largest bolus dose of 400 mg ST/kg BW at
which the highest SO concentration is found.
3.2.2. Human
Concentration-time curves of SO in blood of a resting adult
human (70 kg) who receives single or divided oral doses of ST of
100, 40, 4, or 1 mg/kg BW for 2 w were calculated by the PT model
and are shown in Figs.10 and 11. The time period of 14 d of repeated
exposures was chosen because there is some SO accumulation in
humans in contrast to rats. It requires about 12 d until steady state
J.G. Filser, H.-P. Gelbke / Toxicology Letters 247 (2016) 11–28 19is reached. This is because the ﬁnal, ﬁrst-order elimination phase of
ST, representing the elimination from its storage, the adipose
tissue, is by far longer in humans (elimination half-life of 55 h as
calculated by the PT model for a 70-kg human) than in rats
(elimination half-life of 1.8 h, calculated by the PT model for a
250-g rat). These data are in agreement with published ﬁnal
elimination half-lives of the lipophilic ST of 2–4 d in the adipose
tissue of humans (Engström et al., 1978) and of 3.6  2.76 h in rats
(Ramsey and Young, 1978). A very large difference in the species-
speciﬁc half-lives of the last elimination phase can also be expected
from allometrical scaling by taking into account the species-
speciﬁc volumes of the adipose tissue in both species and the
available (human or rat) elimination rate constant which is linked
to the corresponding ﬁnal elimination half-life of ST (see equation
































Fig. 5. PT-model-calculated concentration-time curves of styrene (ST, A) and styrene-7,8
4 w) by inhalation to vaporous ST at a concentration of 75 ppm (according to the experime
set to 130 g, 157 g, 184 g, and 211 g for the ﬁrst, second, third, and fourth week of expoGenerally, the ﬁndings in humans resemble those in rats. Bolus
doses result in higher values of CmaxSO than divided ones except the
largest daily doses (100 mg/kg BW). The SO peaks are wider after
the largest dose of ST (bolus or divided) as compared to the smaller
doses.
3.3. CmaxSO and AUCSO resulting from inhalation or oral exposures to ST
Table 3 shows daily doses of ST taken in by rats or humans
exposed to ST by inhalation or the oral route. Also given are PT-
model calculated CmaxSO values and daily AUCSO values resulting






-oxide (SO, B) in venous blood of a male F344 rat exposed repeatedly (6 h/d, 5 d/w,
ntal design of Gaté et al., 2012). At the start of the study, the rat was 6 w old. BW was
sure, respectively.
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3.3.1.1. Oral intake of ST
3.3.1.1.1. Rat. Model-calculated values of CmaxSO are proportional
to the oral dose of ST for the two lowest doses of 4 and 40 mg/kg
BW/d, administered once or divided. The CmaxSO at the highest dose
of 400 mg ST/kg BW/d (bolus or divided dose; about 0.3 mg/ml),
however, is only 3 times higher than that from the bolus dose of
40 mg ST/kg BW/d or 6 times higher than that resulting from the
divided doses of 3  40/3 mg ST/kg BW/d (see also Figs. 8 and 9)
although the doses differ by a factor of 10. Obviously, saturation
kinetics of the SO formation becomes relevant. The model-
predicted CmaxSO that cannot be surpassed is in the rat 0.33 mg/
ml (see Fig. 2). It is almost reached at 400 mg ST/kg BW, the highest
modelled oral dose.
3.3.1.1.2. Human. After both the bolus dose and the three times
































Fig. 6. PT-model-calculated concentration-time curves of styrene (ST, A) and styrene-7,8
4 w) by inhalation to vaporous ST at a concentration of 1000 ppm (according to the exper
was set to 130 g, 157 g, 184 g, and 211 g for the ﬁrst, second, third, and fourth week of same CmaxSO of about 0.031 mg/ml in venous blood. Based on
calculations by means of the PT model, it is predicted that the
concentration of metabolically produced SO in venous blood
cannot surpass 0.036 mg/ml. Of this concentration, 95% are reached
in a resting human with a BW of 70 kg at a daily oral dose of
200 mg/kg BW. The predicted maximum possible SO concentration
in ST-exposed humans is by a factor of 9 lower than the
corresponding one in rats. In humans, saturation kinetics of ST
becomes apparent even at the second highest bolus dose of 40 mg/
kg BW/d because the CmaxSO of 0.0248 mg/ml is only about half the
concentration that is obtained by a linear extrapolation of the
values of CmaxSO that were calculated by the PT model for the two
lower bolus doses of 4 and 1 mg ST/kg BW/d. At these two doses,
single and divided dosing results in an about 2-fold difference in
the values of CmaxSO. These values are proportional to the dose of ST
following daily single or divided intake. When 40 mg ST/kg BW/d is
taken in, the difference in the CmaxSO values resulting from single






-oxide (SO, B) in venous blood of a male F344 rat exposed repeatedly (6 h/d, 5 d/w,
imental design of Gaté et al., 2012). At the start of the study, the rat was 6 w old. BW
exposure, respectively.















Fig. 7. PT-model-calculated concentration-time curve of styrene-7,8-oxide (SO) in venous blood of a male F344 rat exposed repeatedly (6 h/d, 5 d/w, 4 w) by inhalation to
vaporous SO at a concentration of 75 ppm (according to the experimental design of Gaté et al., 2012). The rat was 6 w old at the start of the study. BW was set to 130 g, 157 g,
184 g, and 211 g for the ﬁrst, second, third, and fourth week of exposure, respectively.
J.G. Filser, H.-P. Gelbke / Toxicology Letters 247 (2016) 11–28 21because saturation kinetics of the metabolism of ST to SO becomes
evident following intake of the bolus dose of ST. However, after
intake of 40 mg ST/kg BW/d in 3 divided doses of 13.33 mg ST/kg
BW/d each, the proportionality between CmaxSO and dose seen at
the two lowest divided doses still exists. When 100 mg ST/kg BW/d
are taken in, dividing the dose has almost no effect on CmaxSO. Here,
the ST concentration in the liver remains high enough for several
hours for the SO formation rate to become rather near to its
maximum value and without major changes as a result from the
saturation of its metabolic formation from ST, independently of
whether the dose of ST is taken in undivided or divided (see also
Figs. 10 and 11).
3.3.1.2. Inhalation of ST or SO versus oral intake of ST
3.3.1.2.1. Rat. In the venous blood of rats that are exposed to ST
(6 h/d) by inhalation, predicted values of CmaxSO increase roughly
linearly up to a ST concentration of 350 ppm. At higher
concentrations of ST in air, values of CmaxSO approach a plateau
because of the saturation of the ST metabolism (Fig. 2). After
administering daily an oral bolus of 4 mg ST/kg BW to rats, the
resulting CmaxSO is almost twice as high as that resulting from a 6-h
intake of the same ST dose by inhalation (exposure to 9 ppm). This
is also the case when comparing CmaxSO resulting from daily oral
intake of an ST bolus of 40 mg/kg BW with that from daily 6-h
exposures to 75 ppm of ST (daily SO dose of 36.6 mg/kg BW).
Dividing the orally administered amounts in three equal parts
results in almost the same values of CmaxSO per mg of ST per kg BW
as obtained after ST inhalation of similar amounts thus showing
the resemblance between divided oral administrations and
continuous inhalation intake of ST. The highest oral dose of
400 mg ST/kg BW differs by about 20% from the doses inhaled
during 6-h exposures to 1000 ppm of ST (Table 3). Because of
saturation of the ST metabolism, both routes of exposure lead to
almost the same CmaxSO of about 0.3 mg/ml. Saturation of the
metabolism of ST is one cause for the fact that CmaxSO values
reached during exposure to 1000 ppm of ST are nearly 4-fold lower
than the CmaxSO values resulting from inhalation exposure to
75 ppm of SO (see also Figs. 6 and 7).
3.3.1.2.2. Human and comparison with rat. In humans, the picture
is similar to that in rats (Table 3): A daily dose of ST of 1 mg/kg BWleads to higher CmaxSO values when administered orally (as bolus or
as a divided one) than when inhaled by a resting human during an
8-h period (exposure to 7 ppm of ST).
A comparison of the CmaxSO values between humans and rats
resulting from exposures to equal ST doses/kg BW shows lower
values in humans. Following inhalation exposures to low concen-
trations of ST (rat, 6 h/d; human, 8 h/d) model-calculated CmaxSO
values are 4 times lower in the venous blood of humans than in
that of rats which inhale the same amount of ST per kg BW (e.g.
0.0053/3.87/(0.000354/1.02)  4; see Table 3). The same difference
results from a daily single bolus of 40 mg ST/kg BW. It diminishes to
a factor of about two following the daily oral intake of divided ST
doses of 40 mg/kg BW or of single and divided ST doses of 4 mg/kg
BW. At oral ST doses higher than 40 mg/kg BW, the difference
increases again because ST metabolism in humans is saturated at a
lower dose of ST/kg BW than in rats.
In summary, the values of CmaxSO cannot surpass an upper limit
because of the saturation kinetics of ST. CmaxSO values are higher
following single oral bolus doses of ST than after inhalation of the
same amounts of ST. Divided doses of ST result in lower CmaxSO
values than single bolus doses except at high doses of ST at which
its metabolism is saturated. At the same doses of ST per kg BW,
CmaxSO values are higher in rats than in humans.
3.3.2. Daily AUCSO values
The area under a concentration-time curve of a directly DNA-
alkylating substance like SO (e.g., González-Pérez et al., 2014) in
the target tissue is generally considered as a more appropriate dose
metric than a peak concentration (e.g. Ehrenberg et al., 1974; EPA,
2006). Daily AUCSO values in venous blood of rats and humans,
calculated for various scenarios of exposure to ST (and for one to
SO; rats only), are summarized in Table 3 together with daily doses
of ST taken in per kg BW. By using this data set, two linear
regression curves through the origin were constructed (Fig. 12). In
rats, the daily AUCSO [mg SO  h/ml blood] = 0.01057 times the daily
dose of ST [mg/kg BW] with a standard error of the slope of
0.000520 (mg SO  h/ml)/(mg ST/kg BW). The linear regression
curve that is based on 11 calculated AUCSO values for rats is valid for
up to a dose of ST of at least 488 mg/kg BW. In humans, the
corresponding slope with its standard error is
0.00457  0.0000728 (mg SO  h/ml)/(mg ST/kg BW). The linear
Table 3
Daily doses of styrene (ST), PT-model-calculated maximum concentrations of styrene-7,8-oxide (SO) in venous blood (CmaxSO), and areas under the model-calculated
concentration-time curves of SO in venous blood from t = zero to inﬁnity (AUCSO) of resting rats or resting humans resulting from various exposures to ST or SO.
Reference (Figure) Species (kg
BW)
Exposure Daily dose of STc [mg/kg BW] CmaxSO [mg/
ml]
AUCSO per day of exposure [mg  h/ml]
Sinha et al. (1983) (no Figure) Rat
(0.612)a
ST, inhalation,
6 h/d, 5 d/w,
12 m; 1000 ppm
319d 0.306 4.52
Kligerman et al. (1993) (Fig. 4) Rat
(0.136)b
ST, inhalation,
6 h/d, 14 d;
500 ppm
263d 0.252 2.75
Gaté et al. (2012) (Fig. 5) Rat
(0.171)b
ST, inhalation,
6 h/d, 5 d/w, 4 w; 75 ppm
36.6d 0.0482 0.295
Gaté et al. (2012) (Fig. 6) Rat
(0.171)b
ST, inhalation,
6 h/d, 5 d/w,
4 w; 1000 ppm
488d 0.313 4.38
Gaté et al. (2012) (Fig. 7) Rat
(0.171)b
SO, inhalation,
6 h/d, 5 d/w,
4 w; 75 ppm
– 1.16 6.98
Present work (no Figure) Rat
(0.250)
ST, inhalation,
6 h; 9.0 ppm
3.87d 0.00530 0.0334
Present work (Fig. 8) Rat
(0.250)
ST, orally, once daily, 5 d 400 0.308 4.11
40 0.100 0.398
4 0.00935 0.0358
Present work (Fig. 9) Rat
(0.250)
ST, orally, three times daily, 5 d 3  400/3 0.300 4.41
3  40/3 0.0507 0.376
3  4/3 0.00480 0.0356
Present work (no Figure) Human
(70.0)
ST, inhalation, 8 h/d, 5 d;
7.0 ppm
1.02d 0.000354 0.00333
Present work (Fig. 10) Human
(70.0)




Present work (Fig. 11) Human
(70.0)
ST, orally, three times daily,14 d 3 100/3 0.0315 0.475
3  40/3 0.0214 0.192
3  4/3 0.00204 0.0151
3 1/3 0.000494 0.00367
a Estimated average body weight (BW) over the exposure period, calculated for a male Sprague-Dawley rat fed NIH-31 diet ad libitum by using the body weight gain given in
Lewis et al. (2003).
b BW averaged over the exposure period.
c Days free of exposure not considered.
d Calculated as the product of the atmospheric concentration of ST with the alveolar ventilation and the time span of exposure, then related to kg BW (example for a 6-h
exposure of a 250-g rat to 1000 ppm of ST: 1000 (ppm in air)/24450 (ml; molar volume of an ideal gas at 25 C at 101.3 kPa)  104 (mg; micro-molecular weight of
ST)  4210 (ml/h; alveolar ventilation of a 250-g rat at rest; Csanády et al., 1994)  6 (h; exposure period)  1000/250 (1000/BW of the exposed rat ! mg per kg BW) /
1000 (mg ! mg) = 429.8 mg/kg BW; the alveolar ventilation for a BW differing from 250 g was scaled allometrically by BW2/3, for instance the alveolar ventilation of a 130-g rat
is 4210  (130/250)2/3 = 2722 ml/h).
22 J.G. Filser, H.-P. Gelbke / Toxicology Letters 247 (2016) 11–28regression curve that is based on 9 calculated AUCSO values for
humans is valid for up to a dose of ST of at least 100 mg/kg BW. The
relative standard error of the slope is larger in rats (4.92%) than in
humans (1.59%). The difference stems largely from the fact that
the modelled BWs of the animals were variable (between 0.136 and
0.612 kg) whereas a constant BW of 70 kg was used for humans (see
Table 3).
The daily AUCSO in a rat at rest is 2.3-fold that in a resting human
if related to the same dose of ST/kg BW. It is independent of the
exposure regimen (inhalation, undivided or divided oral dosing).
Saturation kinetics of ST doesn’t show an inﬂuence on the dailyAUCSO in the investigated dose ranges of up to 488 (rat) or 100
(human) mg ST/kg BW/d. This observation results from the
following: At high atmospheric ST concentrations at which ST
metabolism is saturated, ST enriches to relatively higher levels in
the organism than at lower concentrations. Consequently, SO
formation lasts over longer time periods at high formation rates
than at low ST concentrations at which the SO formation rate is
limited by the actual ST concentration (compare Figs. 5 and 6). As a
result, the AUCSO (not the concentration of SO) may further
increase linearly with the dose of ST in spite of the saturation
kinetics of ST.

















Fig. 8. PT-model-calculated concentration-time curves of styrene-7,8-oxide (SO) in venous blood of a rat (BW: 250 g) resulting from daily (5 d) repeated oral administrations
of doses of styrene (ST) of 400 (red), 40 (purple), or 4 (blue) mg/kg BW. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web
version of this article.)
















Fig. 9. PT-model-calculated concentration-time curves of styrene-7,8-oxide (SO) in venous blood of a rat (BW: 250 g) resulting from three times (time intervals of 3 h) daily
(5 d) repeated oral administrations of doses of styrene (ST) of 400/3 (red), 40/3 (purple), or 4/3 (blue) mg/kg BW. (For interpretation of the references to colour in this ﬁgure
legend, the reader is referred to the web version of this article.)
J.G. Filser, H.-P. Gelbke / Toxicology Letters 247 (2016) 11–28 23In rats or humans when receiving a deﬁned dose of ST either by
inhalation at rest or by oral exposure, the species-speciﬁc daily
AUCSO values are approximately the same for both exposure
scenarios (Table 3).
3.4. Is a genotoxic risk by SO to be expected from oral intake of ST?
SO was mutagenic in most bacterial assays without an
exogenous metabolic system, in Schizosaccharomyces, Allium
cepa, and Drosophila melanogaster (summarized in IARC (1994).
The lowest effective SO concentration (LEC) was generally rather
high (	24 mg/ml). Only in four out of 39 clearly positivemutagenicity studies with SO, lower LECs were reported. In
Drosophila Melanogaster, sex-linked recessive lethal mutations
were found at an atmospheric LEC of 1 mg/ml. Because SO enriches
drastically in exposed organisms (mean value of the mammalian
blood:air-partition coefﬁcient: 2370 at 37 C; Csanády et al., 1994),
the LEC within the exposed ﬂies was surely much higher than the
SO concentration in the atmosphere. IARC (2002) reports a study
with Drosophila melanogaster, in which the LEC leading to somatic
mutation was 600 mg SO/ml in feed. IARC (1994) stated that Vainio
et al. (1976) should have detected LECs of 0.6 mg/ml in the
Salmonella typhimurium strains TA 100 and TA 1535 and of 6.0 mg/
ml in the strain TA 1538. However, the SO concentrations are given















Fig. 10. PT-model-calculated concentration-time curves of styrene-7,8-oxide (SO) in venous blood of a human at rest (BW: 70 kg) resulting from daily (14 d) oral intake of
doses of styrene (ST) of 100 (green), 40 (purple), 4 (blue), or 1 (black) mg/kg BW. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the
web version of this article.)















Fig. 11. PT-model-calculated concentration-time curves of styrene-7,8-oxide (SO) in venous blood of a human at rest (BW: 70 kg) resulting from three times (time intervals of
3 h) daily (14 d) repeated oral intake of doses of styrene (ST) of 100/3 (green), 40/3 (purple), 4/3 (blue), or 1/3 (black) mg/kg BW. (For interpretation of the references to colour
in this ﬁgure legend, the reader is referred to the web version of this article.)
24 J.G. Filser, H.-P. Gelbke / Toxicology Letters 247 (2016) 11–28in the original publication in mol/plate but not per ml (Vainio et al.,
1976). Also, Vainio et al. (1976) reported that SO “was not
mutagenic to . . . TA 1538”. Obviously, IARC (1994) gave incorrect
information on this publication.
According to the literature summarized in IARC (1994, 2002),
the LEC in non-human mammalian cells in vitro was 90 mg/ml for
both chromosomal aberration and micronucleus formation,
3.6 mg/ml for DNA strand breaks, and 13.8 mg/ml for gene
mutation. The LECs leading in human cells in vitro to micronucleus
formation, chromosomal aberrations, and to DNA strand breaks
were 12 mg/ml, 3 mg/ml (interpreted by IARC (1994) from a ﬁgure
in the publication of Pohlová et al., 1985), and 1.2 mg/ml,
respectively. The LEC for gene mutation in human cells in vitrowas 24 mg/ml (IARC, 2002). Laffon et al., (2001, 2002) investigated
the genotoxicity of SO in a concentration range of between 1.2 and
24 mg SO/ml (10 and 200 mmol/l) using leukocytes of four healthy
non-smoking donors (2 females, 2 males). The authors evaluated
genotoxicity by means of the alkaline comet assay, micronucleus
formation and sister-chromatid exchanges. LECs for signiﬁcant
increases in the frequencies of DNA damage (comet assay),
micronuclei, and sister-chromatid exchanges were 2.4 mg/ml
(20 mmol/l), 12 mg/ml (100 mmol/l), and 6 mg/ml (50 mmol/l),
respectively.
The CmaxSO that can be reached for a short period of time during
daily 6-h exposures of rats to 75 ppm SO (according to Gaté et al.,
2012) is 1.16 mg/ml (Fig. 7; Table 3). The model-calculated CmaxSO



































Fig.12. Daily areas under the PT model-calculated concentration-time curves of styrene-7,8-oxide (SO) in venous blood (AUCSO) of male and female rats and of humans versus
the doses of styrene (ST) taken in. Data points (10 for male rats, 1 (full symbol) for female rats, and 9 for humans; some not visible because of overlapping) were taken from
Table 3. Curves are linear regression lines through the origin  95% conﬁdence bands of the ﬁtted lines. The slopes m of the linear functions (AUCSO = m  dose of ST) and their
standard errors are m = 0.01057  0.000520 (mg SO  h/ml)/(mg ST/kg BW) in rats and m = 0.00457  0.0000728 (mg SO  h/ml)/(mg ST/kg BW) in humans. The coefﬁcients of
determination (r2) are 0.9533 (rats) and 0.9966 (humans).
J.G. Filser, H.-P. Gelbke / Toxicology Letters 247 (2016) 11–28 25values in rat and human that can be reached during exposures to ST
cannot surpass 0.33 mg/ml and 0.036 mg/ml, respectively (see
above). These maximum possible SO concentrations are 3.6-fold
and 33-fold smaller than the lowest LEC value of 1.2 mg/ml.
Therefore, it is not surprising that the in-vivo inhalation studies of
Sinha et al. (1983), Kligerman et al. (1993) and Gaté et al. (2012)
with ST concentrations of up to 1000 ppm were negative with
respect to the induction of micronuclei, chromosomal aberrations,
and DNA strand breaks. A small increase occurred in the frequency
of sister chromatid exchange (Kligerman et al., 1993). However, the
mechanism of the formation and the biological signiﬁcance of
small increases in sister chromatid exchanges is uncertain
(Henderson and Speit, 2005). The small, not dose-dependent
increase in DNA damage observed in the comet assay in the
presence of FPG after three days of exposure to ST but not to SO
(Gaté et al., 2012) was likely a random result (see Section 3.1.2 and
Appendix A).Internal dose metrics that can be useful for estimating the SO-
related genotoxic risk in rats and humans are CmaxSO, AUCSO, and
ACBSO, the lifetime average concentration of SO in venous blood (in
analogy to EPA, 2006).
3.4.1. CmaxSO
Daily oral administrations of a single dose of ST of 400 mg/kg
BW to rats result in a calculated CmaxSO of 0.308 mg SO/ml (Table 3).
A value of CmaxSO of 1.16 mg SO/ml (Table 3) was obtained by the PT
model for the SO exposure-study of Gaté et al. (2012) that was
negative for micronucleus formation and negative in the comet
assay with or without FPG. Oral exposure of humans to 100 mg ST/
kg BW/d (factor of 100 above the exposure at the OML) divided into
3 equal daily doses would lead to a CmaxSO of 0.0315 mg/ml
(Table 3). This concentration is 36.8 times lower than the CmaxSO
associated with daily inhalation exposure (6 h) of rats to 75 ppm of
SO. In addition, it should be taken into consideration that the
Table 4
Safety factors of the dose surrogates for genotoxic effects of styrene-7,8-oxide (SO) in rats and humans: maximum concentration of SO in venous blood (CmaxSO), area under
the concentration-time curve of SO in venous blood (AUCSO), and lifetime average concentration of SO in venous blood (ACBSO).
Parameter Rat Human
Exposure SO inhalation





Safety factor related to CmaxSO 1 36.8 2350
Safety factor related to AUCSO per exposure day 1 15.3 1530
Exposure ST inhalation





Safety factor related to ACBSO 1 3.53 353
a Study of Gaté et al. (2012), no genotoxic effect, calculated CmaxSO = 1.16 mg/ml, calculated AUCSO per exposure day = 6.98 mg  h/ml, study chosen because of the highest
values of CmaxSO and AUCSO of all of the studies dealt with (see Table 3).
b Study of Sinha et al. (1983), no genotoxic effect, calculated ACBSO = 0.067 mg/ml, study chosen because of the highest value of ACBSO of all of the studies dealt with.
c Estimated maximum daily ST intake according to the Overall Migration Limit in the EU, the maximum permitted amount of a substance released from a material or article
into food.
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human are already very close to the PT model-calculated CmaxSO
value that cannot be exceeded in humans by any ST exposure level.
Daily oral ST intake of 1 mg/kg BW in 3 divided doses of 0.33 mg/kg
BW each was calculated to lead in humans to a value of CmaxSO of
0.000494 mg/ml (Table 3) which is 2350-fold smaller than that
resulting from exposure of rats to 75 ppm SO for 6 h.
3.4.2. AUCSO
When rats or humans at rest receive ST orally instead of inhaling
it, the daily species-speciﬁc AUCSO is the same for both exposure
scenarios based on the amount of ST absorbed (see Section 3.3.2).
When using the AUCSO as dose metric, it follows that any genotoxic
risk of SO in the target tissue blood should be the same,
independently whether the exposure to ST is by inhalation at rest
or by the oral route, provided that the same amount of ST is taken
in. The highest daily AUCSO of 6.98 mg  h/ml (Table 3) was
calculated for the repeated exposures of rats to 75 ppm of SO (Gaté
et al., 2012). The daily AUCSO calculated for the one-year exposures
to 1000 ppm of ST (Sinha et al., 1983) was 65% of this value. In the
four-week exposures to 1000 ppm of ST (Gaté et al., 2012) and the
two-week exposures to 500 ppm of ST (Kligerman et al., 1993), the
daily AUCSO values were 63% and 39% of that obtained for the
exposures to 75 ppm of SO. The AUCSO values of the four studies
(Table 3) support each other with respect to the negative
genotoxicity of SO. Assuming that the same daily AUCSO is linked
to the same genotoxic risk of SO in rats and in humans, no
genotoxic effects are to be expected in humans up to a daily AUCSO
of 6.98 mg  h/ml. This value is 15.3 and 1530 times larger than the
daily AUCSO values of 0.457 and 0.00457 mg  h/ml calculated for a
human by means of the linear regression (Fig. 12) for a daily oral ST
intake of 100 and 1 mg/kg BW, respectively.
3.4.3. ACBSO
The study of Sinha et al. (1983) with ST concentrations of
600 and 1000 ppm had the longest exposure period (6 h/d, 5 d/w,
12 m) of the three negative genotoxicity studies with ST (Sinha
et al., 1983; Kligerman et al., 1993; Gaté et al., 2012). Taking into
account a rat life expectancy of 2 years, the ACBSO for the one-year
exposure of rats to 1000 ppm of ST (Sinha et al., 1983) is calculated
according to Reitz et al. (1988) from the daily AUCSO (=4.52 mg SO
 h/ml; Table 3) to ACBSO = 4.52/24  5/7  52/104  0.067 mg SO/
ml. The ACBSO values in a human (70 kg BW) who is orally exposed
for the whole lifetime to daily amounts of ST of 100 or 1 mg ST/kg
BW are 0.019 and 0.00019 mg SO/ml, respectively (ACBSO = daily
AUCSO/24, with daily AUCSO values of 0.457 mg SO  h/ml (daily100 mg ST/kg BW) and 0.00457 mg  h/ml (daily 1 mg ST/kg BW)
calculated by means of the linear function given in Fig. 12B). These
ACBSO values are 3.53- and 353-fold smaller, respectively, than that
resulting from an ST exposure concentration of 1000 ppm in the
one-year rat study of Sinha et al. (1983).
The safety factors of the three dose surrogates for genotoxic
effects of SO for human exposures to ST relative to those in rat
studies are summarized in Table 4.
In conclusion, independently of the dose metric for SO chosen
(CmaxSO, AUCSO, or ACBSO), the dose level that can be reached after
oral intake of daily amounts of ST of 100 mg/kg BW or less is below
that reached in negative genotoxicity studies with ST or SO.
Considering that daily amounts of ST taken in according to the OML
are 100 fold lower, a genotoxic risk of SO to humans from oral
exposure to ST can be excluded.
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Appendix A.
Comments to the results of the comet assay in the presence of FPG
(Gaté et al., 2012)
The study of Gaté et al. (2012) clearly shows that high systemic
concentrations of ST and SO do not induce clastogenic effects or
DNA damage in the “standard” comet assay. On the other hand, the
positive results obtained with ST in the FPG modiﬁcation of the
comet assay might indicate potential oxidative damage after a
short-term exposure to ST. Therefore, in addition to the above
formulated criticism on this particular study (see Section 3.1.2), a
more detailed interpretation of the ﬁndings obtained by the FPG
modiﬁcation is necessary taking into account methodological
aspects of this relatively new method as well as details of the study
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popular, the FPG modiﬁcation is not mentioned in the validated
OECD guideline for the alkaline comet assay (OECD, 2014). Thus,
the “standard” comet assay may be considered as a well-
established routine method but not its FPG modiﬁcation. The
FPG modiﬁcation of the comet assay speciﬁcally enables detection
of oxidative DNA damage (Collins et al., 1996; Speit et al., 2004), by
incubation of cellular DNA with the FPG enzyme. But apart from
these oxidation products also DNA modiﬁcations, like alkylations,
showing up in the “standard” comet assay are detected as well (e.g.
Speit et al., 2004; Smith et al., 2006). The European Comet Assay
Validation Group (ECVAG) undertook a major effort to standardize
the FPG modiﬁcation of the comet assay. These investigations
showed that a substantial number of participating laboratories,
although rating themselves as having high or medium experience
with the comet assay, had problems in performing this assay
(Forchhammer et al., 2012; Ersson et al., 2013; Godschalk et al.,
2014). This corresponded to results of an earlier inter-laboratory
trial of the European Standards Committee on Oxidative DNA
Damage (ESCODD, 2003). In a later trial a better performance was
reported for most of the participating laboratories (Johansson
et al., 2010) but this could be explained by differences in cells
provided as reference materials. A comparison of two different
ESCODD studies (ESCODD, 2003; ESCODD et al., 2005) showed
large (10 times) differences in the levels of FPG sensitive sites
between the laboratories (Møller, 2006). It should be taken into
consideration that none of these inter-laboratory comparisons
used typical chemical mutagens apart from RO19-8022, a
substance generating speciﬁc oxidative DNA damage after light-
exposure. To our knowledge, other chemicals suspected as
mutagens have not yet been included in such trials. As the FPG
modiﬁcation is still under validation and an OECD guideline does
not exist, in contrast to the “standard” comet assay, data by the FPG
assay should be analysed with caution. It can be concluded that
even laboratories with good experience with the “standard” assay
may obtain unsatisfactory results by the FPG modiﬁcation. Taking
into account general methodological problems associated with the
FPG assay and the incompatibilities of the results obtained by Gaté
et al. (2012) when using FPG with the blood burdens of ST and SO
(see Section 3.1.2), this study must be interpreted with caution and
not too much weight can be given to the positive ﬁndings in the
FPG assay with ST.
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